Novocure LTD 8-K filings

The FDA has approved Optune Lua for concurrent use with certain therapies in adult patients with metastatic non-small cell lung cancer who have progressed after platinum-based treatment.

NovoCure is undergoing a leadership transition with the current CEO retiring and the CFO stepping into the role, along with other key management changes.

NovoCure announced a 19% year-over-year increase in net revenues for the second quarter of 2024, reaching $150 million, alongside positive clinical trial results.

NovoCure's annual shareholder meeting resulted in the election of ten directors and the approval of the 2024 Omnibus Incentive Plan.

NovoCure will present the results of its METIS phase 3 clinical trial for brain metastases from non-small cell lung cancer at the 2024 ASCO Annual Meeting.

NovoCure announced a 13% year-over-year increase in net revenues for Q1 2024, driven by successful launches and improved approval rates, alongside positive clinical trial results.

NovoCure's phase 3 METIS trial demonstrated a statistically significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer treated with Tumor Treating Fields (TTFields) therapy.

NovoCure reported a 5% decrease in full-year revenue for 2023, but saw a 4% increase in fourth-quarter revenue, and completed key clinical trial enrollments.

The FDA has accepted NovoCure's application for its Tumor Treating Fields therapy in non-small cell lung cancer, marking a significant step towards potential approval.